Design Therapeutics

Design Therapeutics develops GeneTACs, small-molecule therapies for inherited nucleotide repeat expansion diseases like Friedreich ataxia.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series B
Initial Investment Year
2021